Who is sponsoring NCT03634293?

NCT03634293 is sponsored by Wolfson Medical Center.

What condition does NCT03634293 study?

NCT03634293 studies Sepsis, Septic Shock.

What drugs are being tested in NCT03634293?

Interventions: Alirocumab Injectable Product, Saline Solution.

What is the status of NCT03634293?

NCT03634293 is currently UNKNOWN.

Last reviewed 2018-08-13 · How we verify

PCSK9 Inhibitor: a New Tool to Fight Septic Shock

NCT03634293 Phase 2/Phase 3 UNKNOWN

Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors increase LDL receptors by decreasing its degradation. In sepsis the pathogenic substances, endotoxin, lipoteichoic acid, phospholipomannan are the main cause of the ongoing inflammation that causes the severe damage and outcome. these substances are removed from the blood by the LDL receptors. By administering PCSK9 inhibitors to patients with sepsis/septic shock this inflammatory response can be stopped and by doing so improve the patients outcome.

Details

Lead sponsor	Wolfson Medical Center
Phase	Phase 2/Phase 3
Status	UNKNOWN
Enrolment	712
Start date	2019-01
Completion	2021-02

Conditions

Sepsis
Septic Shock

Interventions

Alirocumab Injectable Product
Saline Solution

Primary outcomes

survival — At 28 days from randomization
We will measure the survival at 28 days

Countries

Israel